The collaboration positions Everest to allow better access to its new drugs
SHANGHAI, July 13, 2021 / PRNewswire / – Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development and commercialization of transformative pharmaceuticals that meet the critical unmet medical needs of patients in Greater China and other parts of Asia, today announced that it has entered into a strategic collaboration with Medbanks Health Technology, a pharmacy and healthcare service provider specializing in oncology.
The collaboration of the companies will focus on leveraging the nation’s specialized network of direct-to-patient pharmacies to explore innovative healthcare solutions for oncology and specialty care, including a new service model to address unmet needs. of patients in these extensive pathological areas. This collaboration positions Everest to allow patients better access to its new drugs.
In addition, the companies will collaborate on patient education, explore opportunities to collect real-world data using Medbanks’ database and outpatient care system, and work to establish a model to improve patient care. disease management for oncology and other critical illnesses via the Medbanks online platform. and a team dedicated to patient service.
“This strategic collaboration will lay a solid foundation for educating patients and healthcare providers on the availability of new, innovative medicines, and enable physicians to more effectively manage patients and their illnesses, promoting improved health and the quality of life of patients ”, declared Kerry Blanchard, MD, PhD, CEO of Everest Medicines. “This is an important milestone for Everest as we continue to prepare and work on bringing our products to market.”
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products that meet the critical unmet medical needs of patients in Greater China and other Asian markets. The Everest Medicines management team has deep expertise and extensive experience in clinical development, regulatory affairs, CMC, business development and high quality operations, both in the field China and with the world’s leading pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-class or first-class molecules, many of which are at an advanced stage of clinical development. The therapeutic areas of interest of the Company include oncology, autoimmune diseases, cardio-renal diseases and infectious diseases. For more information, please visit their website at www.everestmedicines.com.
About Medbanks Health Technology
Medbanks Health Technology was founded in 2014 with seven years of history. Medbanks has formed a special network of pharmaceutical services, a network of professional clinicians and a medical network covering the whole country on the basis of the four infrastructure elements – doctor, medicine, health insurance and data, thus becoming a platform leading integrated professional health care services in oncology and critical illness. At present, the company has set up three head offices in Canton, Beijing, and Shanghai, which includes three enterprise systems: the Medical Innovation Services Business Group, the Drug Innovation Services Business Group, and the Healthcare Innovation Services Business Group.
SOURCE Everest Medicines